Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

DIABETIC KIDNEY DISEASE

Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice

Nature Reviews Nephrology volume 16, pages 433–434 (2020)Cite this article

Subjects

Clinical trials of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2 diabetes mellitus. Two new cohort studies now demonstrate that these findings are generalizable to the broad range of patients seen in clinical practice.

Refers to Pasternak, B. et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian Cohort Study. Br. Med. J. 369, m1186 (2020) | Pasternak, B. et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian Cohort Study. Diabetes Care 43, 1326–1335 (2020).

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Patient cohorts enrolled in clinical trials with SGLT2 inhibitors and GLP1 receptor agonists.

Similar content being viewed by others

References

  1. Zelniker, T. A. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31–39 (2019).

    Article  CAS  Google Scholar 

  2. Kristensen, S. L. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 7, 776–785 (2019).

    Article  CAS  Google Scholar 

  3. Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380, 2295–2306 (2019).

    Article  CAS  Google Scholar 

  4. Giorgino, F., Vora, J., Fenici, P. & Solini, A. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: does it apply to all patients? Diabetes Obes. Metab. https://doi.org/10.1111/dom.14055 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Birkeland, K. I. et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes Obes. Metab. 21, 968–974 (2019).

    Article  CAS  Google Scholar 

  6. Knudsen, J. S., Thomsen, R. W., Pottegård, A., Knop, F. K. & Sørensen, H. T. Differences between randomized clinical trial patients and real-world initiators of the glucagon-like peptide 1 receptor agonist liraglutide. Diabetes Care 41, e133–e135 (2018).

    Article  Google Scholar 

  7. Pasternak, B. et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. Br. Med. J. 369, m1186 (2020).

    Article  Google Scholar 

  8. Pasternak, B. et al. Use of glucagon-like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43, 1326–1335 (2020).

    Article  Google Scholar 

  9. Heerspink, H. J. L. et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 8, 27–35 (2020).

    Article  CAS  Google Scholar 

  10. Heerspink, H. J. L. et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol. Dial. Transplant. 35, 274–282 (2020).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands

    Annemarie B. van der Aart-van der Beek & Hiddo J. L. Heerspink

Authors
  1. Annemarie B. van der Aart-van der Beek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiddo J. L. Heerspink
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiddo J. L. Heerspink.

Ethics declarations

Competing interests

H.L.H. has served as a consultant for AbbVie, Astellas, AstraZeneca, Boehringer Ingelheim, Fresenius, Gilead, Janssen, Merck, Mundipharma, Mitsubishi Tanabe, and Retrophin and has received grant support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen. A.B.v.d.A-v.d.B. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

van der Aart-van der Beek, A.B., Heerspink, H.J.L. Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice. Nat Rev Nephrol 16, 433–434 (2020). https://doi.org/10.1038/s41581-020-0312-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-020-0312-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing